<DOC>
	<DOCNO>NCT02252965</DOCNO>
	<brief_summary>This Phase 4 , prospective , open label , randomize , parallel control multicenter trial metformin extend release ( XR ) compare metformin immediate release ( IR ) gastrointestinal tolerability efficacy newly diagnose subject Type 2 diabetes glycosylated hemoglobin ( HbA1c ) value 7.0 10.0 percent ( % ) .</brief_summary>
	<brief_title>Metformin Extended Release Versus Metformin Immediate Release Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Diagnosis Type 2 diabetes mellitus screen visit base World Health Organization ( WHO ) diagnostic classification criterion HbA1c value 7.010.0 % , inclusive Age range 18 79 year , inclusive Treatmentnaive oral antidiabetic agent ( , receive antidiabetic medication previously , receive antidiabetic medication least 14 day within 1 month enrolment ) Male , nonpregnant , nonbreastfeeding female Body mass index ( BMI ) great equal ( &gt; = ) 18.5 less ( &lt; ) 35 kilogram per square meter ( kg/m^2 ) In opinion investigator , subject wellmotivated , capable willing continue study treatment require whole study period , maintain study dietary , require protocol , attend schedule visit willing receive phone call visit , avoid pregnancy use adequate method contraception throughout duration study female subject child bear potential ( appropriate male subject female partner childbearing potential ) Written informed consent give trialrelated activity carry Exclusion criterion : Type 1 diabetes Previous treatment insulin antidiabetic ( include Chinese traditional medicine ) 14 day continuously within 1 month enrolment Any protocolspecified cardiovascular condition within 3 month prior screen visit Impaired liver function define protocol Serum creatinine value specify protocol Known proliferative retinopathy maculopathy require acute treatment , recurrent major hypoglycemia hypoglycemic unawareness judge investigator Persistent uncontrolled hypertension Severe chronic gastrointestinal disease Previous history 1 episode ketoacidosis hyperosmolar state/coma Currently receive chronic ( &gt; 14 day ) systemic glucocorticoid therapy ( exclude topical , intraocular , inhaled intranasal preparation ) receive therapy within 4 week screen visit Current use betablockers , thiazide diuretic , thyroid product , estrogen , oral contraceptive , phenytoin , nicotinic acid , sympathomimetics , nifedipine isoniazid replace treatment Have hematologic condition may interfere HbA1c measurement ( example , hemolytic anemia , sicklecell disease ) Have condition ( , know drug alcohol abuse psychiatric disorder ) may prevent subject follow complete protocol Known hypersensitivity Metformin Hydrochloride Currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Any contraindication Metformin accord local package insert</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Metformin XR</keyword>
	<keyword>Metformin IR</keyword>
</DOC>